Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline
1. ZTS reported Q2 2025 EPS of $1.76, surpassing estimates. 2. Sales reached $2.50 billion, up 4% year-on-year, also exceeding forecasts. 3. Companion animal products increased 9%, despite livestock product decline of 21%. 4. Raised fiscal 2025 revenue and EPS guidance from earlier forecasts. 5. Investor confidence remains cautious regarding Librela’s performance impact on growth.